Want to see TRDA full AI Analyst Report?

Entrada Therapeutics Inc (TRDA) Price & Analysis

Q: What was Entrada Therapeutics Inc’s price range in the past 12 months?

Entrada Therapeutics Inc lowest stock price was $4.11 and its highest was $16.45 in the past 12 months.

Q: What is Entrada Therapeutics Inc’s market cap?

Entrada Therapeutics Inc’s market cap is $187.67M.

Q: When is Entrada Therapeutics Inc’s upcoming earnings report date?

Entrada Therapeutics Inc’s upcoming earnings report date is Nov 10, 2026 which is in 20 days.

Q: How were Entrada Therapeutics Inc’s earnings last quarter?

Entrada Therapeutics Inc released its earnings results on Aug 05, 2026. The company reported -$1.01 earnings per share for the quarter, beating the consensus estimate of -$1.049 by $0.039.

Q: Is Entrada Therapeutics Inc overvalued?

According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Entrada Therapeutics Inc pay dividends?

Entrada Therapeutics Inc does not currently pay dividends.

Q: What is Entrada Therapeutics Inc’s EPS estimate?

Entrada Therapeutics Inc’s EPS estimate is -1.01.

Q: How many shares outstanding does Entrada Therapeutics Inc have?

Entrada Therapeutics Inc has 38,936,670 shares outstanding.

Q: What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?

Entrada Therapeutics Inc reported an EPS of -$1.01 in its last earnings report, beating expectations of -$1.049. Following the earnings report the stock price went down -2.486%.

Q: Which hedge fund is a major shareholder of Entrada Therapeutics Inc?

Currently, no hedge funds are holding shares in TRDA

164 Followers

TRDA Stock Chart & Stats

$7.62

$0.23(3.93%)

At close: Jul 27 4:00 PM EDT

$7.62

$0.23(3.93%)

Day’s Range― - ―

52-Week Range$4.11 - $16.45

Previous CloseN/A

Volume18.80K

Average Volume (3M)341.21K

Market Cap

$187.67M

Enterprise Value$136.29M

Total Cash (Recent Filing)$223.00M

Total Debt (Recent Filing)$48.54M

Price to Earnings (P/E)―

Beta1.02

Next Earnings

Nov 10, 2026

EPS Estimate

-1.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.97

Shares Outstanding38,936,670

10 Day Avg. Volume372,860

30 Day Avg. Volume341,206

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)1.39

Price to Sales (P/S)16.73

P/FCF Ratio-3.28

Enterprise Value/Market Cap0.73

Enterprise Value/Revenue29.08

Enterprise Value/Gross Profit-3.85

Enterprise Value/Ebitda-0.83

Forecast

1Y Price Target

$19.67

Price Target Upside158.09% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-3.88

Revenue Forecast (FY)$10.65M

Bulls Say, Bears Say

Bulls Say

Intracellular Delivery PlatformEntrada’s EEV platform addresses a central challenge in biologic medicines by targeting intracellular delivery of therapeutic cargoes. If the approach translates across programs, it could support multiple development opportunities in serious diseases rather than relying on a single asset.

Modest LeverageThe relatively low debt burden gives Entrada more financial flexibility than a highly leveraged clinical-stage company. With substantial assets relative to debt, the balance sheet can provide some capacity to continue development while limiting immediate pressure from interest and refinancing obligations.

Clinical Safety And ProgressionFavorable safety and tolerability at the initial 5 mg/kg dose, combined with continued participant enrollment in open-label follow-up, supports ongoing clinical development. Higher-dose cohorts and longer treatment periods now provide defined opportunities to test whether biological activity can improve.

Bears Say

Severe Cash BurnThe company is consuming substantial cash without internally generated funding, increasing reliance on external financing to sustain research and clinical programs. Persistent negative operating and free cash flow can limit strategic flexibility and create dilution or funding pressure over the next several quarters.

Weak And Volatile ProfitabilityVery limited revenue relative to a large net loss shows that Entrada has not established durable operating economics. The reversal from stronger 2024 results to heavy losses, together with recent revenue contraction, makes earnings power difficult to sustain while development spending remains high.

Limited Demonstrated Clinical BenefitThe initial trial data demonstrate only modest biological activity and no observed functional improvement at the tested dose and duration. This leaves the program dependent on higher-dose and longer-term results to establish meaningful patient benefit, creating substantial development uncertainty.

Entrada Therapeutics Inc News

Entrada Therapeutics appoints Linea Aspesi as chief people officer

Entrada Therapeutics (TRDA) announced the appointment of Linea Aspesi as chief people officer. Prior to Entrada, Aspesi served...

2h ago

TRDA

Entrada Therapeutics reports data from Cohort 1 of ELEVATE-45-201 clinical study

Entrada Therapeutics (TRDA) announced topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose, or MAD,...

7d ago

TRDA

Entrada Therapeutics reports positive ENTR-601-45 trial results

An announcement from Entrada Therapeutics Inc ( ($TRDA) ) is now available. On October 14, 2026, Entrada Therapeutics...

7d ago

TRDA

Entrada Therapeutics price target raised to $11 from $10 at Roth Capital

Roth Capital raised the firm’s price target on Entrada Therapeutics (TRDA) to $11 from $10 and keeps a...

2M ago

TRDA

Entrada Therapeutics reports Q2 EPS ($1.01), consensus ($1.04)

Reports Q2 revenue $898,000, consensus $2.23M. “With multiple data readouts ahead in 2026, we are well positioned to...

3M ago

TRDA

Entrada Therapeutics Stockholders Approve Directors and Equity Plans

Entrada Therapeutics Inc ( ($TRDA) ) has issued an announcement. Entrada Therapeutics Inc. held its Annual Meeting of...

4M ago

TRDA

Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim

Guggenheim lowered the firm’s price target on Entrada Therapeutics (TRDA) to $17 from $20 and keeps a Buy...

5M ago

TRDA

Entrada Therapeutics Highlights Transformational Year and Pipeline Progress

The latest announcement is out from Entrada Therapeutics Inc ( ($TRDA) ). On May 18, 2026, Entrada Therapeutics...

5M ago

TRDA

Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital

Roth Capital lowered the firm’s price target on Entrada Therapeutics (TRDA) to $10 from $19 and keeps a...

6M ago

NVS

TRDA

Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju downgraded Entrada Therapeutics (TRDA) to Neutral from Buy without a price target saying...

6M ago

TRDA

Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study

Entrada Therapeutics (TRDA) announced topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of...

6M ago

TRDA

Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst

TD Cowen analyst Joseph Thome has maintained their bullish stance on TRDA stock, giving a Buy rating today....

6M ago

TRDA

Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)

Reports Q1 revenue $875,000, consensus $2.92M. “With the recently announced positive data from Cohort 1 of our ELEVATE-44-201...

6M ago

TRDA

Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data

Entrada Therapeutics Inc ( ($TRDA) ) has issued an announcement. On May 7, 2026, Entrada Therapeutics reported first-quarter...

6M ago

TRDA

TRDA FAQ

What was Entrada Therapeutics Inc’s price range in the past 12 months?

Entrada Therapeutics Inc lowest stock price was $4.11 and its highest was $16.45 in the past 12 months.

What is Entrada Therapeutics Inc’s market cap?

Entrada Therapeutics Inc’s market cap is $187.67M.

When is Entrada Therapeutics Inc’s upcoming earnings report date?

Entrada Therapeutics Inc’s upcoming earnings report date is Nov 10, 2026 which is in 20 days.

How were Entrada Therapeutics Inc’s earnings last quarter?

Entrada Therapeutics Inc released its earnings results on Aug 05, 2026. The company reported -$1.01 earnings per share for the quarter, beating the consensus estimate of -$1.049 by $0.039.

Is Entrada Therapeutics Inc overvalued?

According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Entrada Therapeutics Inc pay dividends?

Entrada Therapeutics Inc does not currently pay dividends.

What is Entrada Therapeutics Inc’s EPS estimate?

Entrada Therapeutics Inc’s EPS estimate is -1.01.

How many shares outstanding does Entrada Therapeutics Inc have?

Entrada Therapeutics Inc has 38,936,670 shares outstanding.

What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?

Entrada Therapeutics Inc reported an EPS of -$1.01 in its last earnings report, beating expectations of -$1.049. Following the earnings report the stock price went down -2.486%.

Which hedge fund is a major shareholder of Entrada Therapeutics Inc?

Currently, no hedge funds are holding shares in TRDA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Entrada Therapeutics Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

-57.61%

Trailing 12-Months

Asset Growth

-33.40%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Entrada Therapeutics Inc

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.

Entrada Therapeutics Inc (TRDA) Earnings & Revenues

Historic Earnings Reports

TRDA Stock 12 Month Forecast

Average Price Target

$19.67

▲(158.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","15":"$15","26":"$26","9.5":"$9.5","20.5":"$20.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.666666666666668,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.5,15,20.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.68,7.166153846153846,8.652307692307692,10.138461538461538,11.624615384615385,13.11076923076923,14.596923076923076,16.083076923076923,17.56923076923077,19.055384615384614,20.54153846153846,22.02769230769231,23.513846153846153,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.68,6.7558974358974355,7.831794871794871,8.907692307692308,9.983589743589743,11.05948717948718,12.135384615384616,13.211282051282051,14.287179487179488,15.363076923076925,16.43897435897436,17.514871794871794,18.590769230769233,{"y":19.666666666666668,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.68,6.089230769230769,6.498461538461538,6.907692307692307,7.316923076923077,7.726153846153846,8.135384615384615,8.544615384615383,8.953846153846154,9.363076923076923,9.772307692307692,10.181538461538462,10.59076923076923,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.88,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.95,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.91,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.28,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.48,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.91,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.59,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.79,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.68,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >